BIOTRONIK Blog Explore our latest insightful interviews and articles Image Blog Stories Filter and Search Filter by year - Any -20252024202320222021 Search 46 blog articles Image Blog 60 Years of Saving Lives & Giving Back – How BIOTRONIK Offices Support Local Communities Our colleagues from around the world show that it sometimes doesn't take much to make a difference Image Blog Women’s History Month: Celebrating the Women Who Helped Shape Cardiology Women’s History Month is the perfect time to celebrate the incredible achievements of the women who have shaped the field of cardiology. Image Blog How to Select ICDs and Foster Early Detection of Atrial Fibrillation The incidence of atrial fibrillation (AF) in patients with implantable cardioverter-defibrillators (ICDs) is approximately 21 percent (mean annual probability) 1 and is often undetected – and therefore untreated. Image Blog Staying Active and Sticking to Goals With a Heart Implant Cardiac pacemaker implantations are now routine interventions. Around three million people worldwide have a pacemaker, and every year 600,000 more receive an implant. Nevertheless, the diagnosis and procedure can look challenging for patients at first— especially patients who are athletes or enjoy being active. Image Blog Resolutions Worth Keeping: Living Heart-Healthy in 2022 An American survey last year found that health-related goals topped the priority list of New Year’s resolutions for 2021. Around half of those surveyed wanted to exercise more or lose weight, while about 40 percent wanted to improve their diets and 10 percent wanted to quit smoking. Of those people who make resolutions, many say they do, in fact, keep them. Around half of respondents in one such survey said they kept at least some of their 2020 resolutions. About 35 percent said they met all of their goals and just 16 percent say they didn’t keep any of their resolutions. Image Blog Five Things All Cardiac Device Patients Should Know Read the Most Common Patient Questions We Received in 2021 and Answers From Our Experts Image Blog First BIO-LIBRA Results Pave Way for More Representative Clinical Trials After starting enrollment in 2019, Dr. Valentina Kutyifa announced the first results of the BIOTRONIK-supported BIO-LIBRA trial at the Annual Heart Rhythm Society meeting (HRS 2022). Image Blog “Discussions With My Daughter Gave Me the Sense That Things Could Continue Normally” BIOTRONIK Employees Share Their Experiences as Relatives of Cardiac Patients Image Blog What Role Can ICMs Play in Stroke Prevention? As ICM Use Becomes More Common, How Can Clinics Manage the Workloads That Come With the Longer-Term Diagnostic Windows ICMs Offer? Pagination Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Previous page ‹ Previous Next page Next › Subscribe for our News You must have JavaScript enabled to use this form. Title Select TitleMsMrMXDrProf First name Last name Role Please select your roleHealthcare ProfessionalPatient or RelativeJournalistOther Email Phone Country/Region - Select -AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua & BarbudaArgentinaArmeniaArubaAscension IslandAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia & HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBritish Virgin IslandsBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCanary IslandsCape VerdeCaribbean NetherlandsCayman IslandsCentral African RepublicCeuta & MelillaChadChileChinaChristmas IslandClipperton IslandCocos (Keeling) IslandsColombiaComorosCongo - BrazzavilleCongo - KinshasaCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d’IvoireDenmarkDiego GarciaDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard & McDonald IslandsHondurasHong Kong SAR ChinaHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacao SAR ChinaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmar (Burma)NamibiaNauruNepalNetherlandsNetherlands AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorth KoreaNorth MacedoniaNorwayOmanOutlying OceaniaPakistanPalauPalestinian TerritoriesPanamaPapua New GuineaParaguayPeruPhilippinesPitcairn IslandsPolandPortugalPuerto RicoQatarRomaniaRussiaRwandaRéunionSamoaSan MarinoSarkSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia & South Sandwich IslandsSouth KoreaSouth SudanSpainSri LankaSt. BarthélemySt. HelenaSt. Kitts & NevisSt. LuciaSt. MartinSt. Pierre & MiquelonSt. Vincent & GrenadinesSudanSurinameSvalbard & Jan MayenSwedenSwitzerlandSyriaSão Tomé & PríncipeTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad & TobagoTristan da CunhaTunisiaTurkmenistanTurks & Caicos IslandsTuvaluTürkiyeU.S. Outlying IslandsU.S. Virgin IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVatican CityVenezuelaVietnamWallis & FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Topic Please select a topicProductsPatientsHealthcare Professionals I prefer to be contacted by Phone Email Message *Fields are mandatory. Latest Press Releases Show all press releases Image February 27, 2025 BERLIN, Germany BIOTRONIK Driving the Future of Active Device Business BIOTRONIK Driving the Future of Active Device Business BIOTRONIK, a global leader in medical technology, and a pioneer in cardiovascular, endovascular, and neuromodulation solutions, today announced a strategic shift to strengthen its leadership in active implantable devices and digital healthcare. Leveraging future technologies, including artificial intelligence (AI), remote patient monitoring and connected healthcare platforms, BIOTRONIK is at the forefront of improving patient outcomes and optimizing clinical workflows. These innovations are designed to enhance the efficiency and accessibility of care, enabling healthcare providers with next Image BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with Image AMSTERDAM, The Netherlands Press Release 12-Month-Data of BIOFLOW-DAPT Study Show Positive Results for Orsiro Mission DES With Short DAPT BIOFLOW-DAPT one-year-data demonstrated non-inferiority and a good safety profile for the Orsiro ® Mission drug-eluting stent (DES) compared to Resolute Onyx DES (p<0.0001) in patients at high risk of bleeding receiving short dual antiplatelet therapy (DAPT). Prof. Marco Valgimigli presented the novel data in a late-breaking trial session at the European Society of Cardiology’s (ESC) Congress in Amsterdam. The results were published simultaneously in Circulation. BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled clinical study to assess the safety of one Press Contact Corporate Public Relations & Communications press@biotronik.com +49 (0) 30 68905 1414 Get in contact
Image Blog 60 Years of Saving Lives & Giving Back – How BIOTRONIK Offices Support Local Communities Our colleagues from around the world show that it sometimes doesn't take much to make a difference
Image Blog 60 Years of Saving Lives & Giving Back – How BIOTRONIK Offices Support Local Communities Our colleagues from around the world show that it sometimes doesn't take much to make a difference
Image Blog Women’s History Month: Celebrating the Women Who Helped Shape Cardiology Women’s History Month is the perfect time to celebrate the incredible achievements of the women who have shaped the field of cardiology.
Image Blog Women’s History Month: Celebrating the Women Who Helped Shape Cardiology Women’s History Month is the perfect time to celebrate the incredible achievements of the women who have shaped the field of cardiology.
Image Blog How to Select ICDs and Foster Early Detection of Atrial Fibrillation The incidence of atrial fibrillation (AF) in patients with implantable cardioverter-defibrillators (ICDs) is approximately 21 percent (mean annual probability) 1 and is often undetected – and therefore untreated.
Image Blog How to Select ICDs and Foster Early Detection of Atrial Fibrillation The incidence of atrial fibrillation (AF) in patients with implantable cardioverter-defibrillators (ICDs) is approximately 21 percent (mean annual probability) 1 and is often undetected – and therefore untreated.
Image Blog Staying Active and Sticking to Goals With a Heart Implant Cardiac pacemaker implantations are now routine interventions. Around three million people worldwide have a pacemaker, and every year 600,000 more receive an implant. Nevertheless, the diagnosis and procedure can look challenging for patients at first— especially patients who are athletes or enjoy being active.
Image Blog Staying Active and Sticking to Goals With a Heart Implant Cardiac pacemaker implantations are now routine interventions. Around three million people worldwide have a pacemaker, and every year 600,000 more receive an implant. Nevertheless, the diagnosis and procedure can look challenging for patients at first— especially patients who are athletes or enjoy being active.
Image Blog Resolutions Worth Keeping: Living Heart-Healthy in 2022 An American survey last year found that health-related goals topped the priority list of New Year’s resolutions for 2021. Around half of those surveyed wanted to exercise more or lose weight, while about 40 percent wanted to improve their diets and 10 percent wanted to quit smoking. Of those people who make resolutions, many say they do, in fact, keep them. Around half of respondents in one such survey said they kept at least some of their 2020 resolutions. About 35 percent said they met all of their goals and just 16 percent say they didn’t keep any of their resolutions.
Image Blog Resolutions Worth Keeping: Living Heart-Healthy in 2022 An American survey last year found that health-related goals topped the priority list of New Year’s resolutions for 2021. Around half of those surveyed wanted to exercise more or lose weight, while about 40 percent wanted to improve their diets and 10 percent wanted to quit smoking. Of those people who make resolutions, many say they do, in fact, keep them. Around half of respondents in one such survey said they kept at least some of their 2020 resolutions. About 35 percent said they met all of their goals and just 16 percent say they didn’t keep any of their resolutions.
Image Blog Five Things All Cardiac Device Patients Should Know Read the Most Common Patient Questions We Received in 2021 and Answers From Our Experts
Image Blog Five Things All Cardiac Device Patients Should Know Read the Most Common Patient Questions We Received in 2021 and Answers From Our Experts
Image Blog First BIO-LIBRA Results Pave Way for More Representative Clinical Trials After starting enrollment in 2019, Dr. Valentina Kutyifa announced the first results of the BIOTRONIK-supported BIO-LIBRA trial at the Annual Heart Rhythm Society meeting (HRS 2022).
Image Blog First BIO-LIBRA Results Pave Way for More Representative Clinical Trials After starting enrollment in 2019, Dr. Valentina Kutyifa announced the first results of the BIOTRONIK-supported BIO-LIBRA trial at the Annual Heart Rhythm Society meeting (HRS 2022).
Image Blog “Discussions With My Daughter Gave Me the Sense That Things Could Continue Normally” BIOTRONIK Employees Share Their Experiences as Relatives of Cardiac Patients
Image Blog “Discussions With My Daughter Gave Me the Sense That Things Could Continue Normally” BIOTRONIK Employees Share Their Experiences as Relatives of Cardiac Patients
Image Blog What Role Can ICMs Play in Stroke Prevention? As ICM Use Becomes More Common, How Can Clinics Manage the Workloads That Come With the Longer-Term Diagnostic Windows ICMs Offer?
Image Blog What Role Can ICMs Play in Stroke Prevention? As ICM Use Becomes More Common, How Can Clinics Manage the Workloads That Come With the Longer-Term Diagnostic Windows ICMs Offer?
Image February 27, 2025 BERLIN, Germany BIOTRONIK Driving the Future of Active Device Business BIOTRONIK Driving the Future of Active Device Business BIOTRONIK, a global leader in medical technology, and a pioneer in cardiovascular, endovascular, and neuromodulation solutions, today announced a strategic shift to strengthen its leadership in active implantable devices and digital healthcare. Leveraging future technologies, including artificial intelligence (AI), remote patient monitoring and connected healthcare platforms, BIOTRONIK is at the forefront of improving patient outcomes and optimizing clinical workflows. These innovations are designed to enhance the efficiency and accessibility of care, enabling healthcare providers with next
Image February 27, 2025 BERLIN, Germany BIOTRONIK Driving the Future of Active Device Business BIOTRONIK Driving the Future of Active Device Business BIOTRONIK, a global leader in medical technology, and a pioneer in cardiovascular, endovascular, and neuromodulation solutions, today announced a strategic shift to strengthen its leadership in active implantable devices and digital healthcare. Leveraging future technologies, including artificial intelligence (AI), remote patient monitoring and connected healthcare platforms, BIOTRONIK is at the forefront of improving patient outcomes and optimizing clinical workflows. These innovations are designed to enhance the efficiency and accessibility of care, enabling healthcare providers with next
Image BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with
Image BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with
Image AMSTERDAM, The Netherlands Press Release 12-Month-Data of BIOFLOW-DAPT Study Show Positive Results for Orsiro Mission DES With Short DAPT BIOFLOW-DAPT one-year-data demonstrated non-inferiority and a good safety profile for the Orsiro ® Mission drug-eluting stent (DES) compared to Resolute Onyx DES (p<0.0001) in patients at high risk of bleeding receiving short dual antiplatelet therapy (DAPT). Prof. Marco Valgimigli presented the novel data in a late-breaking trial session at the European Society of Cardiology’s (ESC) Congress in Amsterdam. The results were published simultaneously in Circulation. BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled clinical study to assess the safety of one
Image AMSTERDAM, The Netherlands Press Release 12-Month-Data of BIOFLOW-DAPT Study Show Positive Results for Orsiro Mission DES With Short DAPT BIOFLOW-DAPT one-year-data demonstrated non-inferiority and a good safety profile for the Orsiro ® Mission drug-eluting stent (DES) compared to Resolute Onyx DES (p<0.0001) in patients at high risk of bleeding receiving short dual antiplatelet therapy (DAPT). Prof. Marco Valgimigli presented the novel data in a late-breaking trial session at the European Society of Cardiology’s (ESC) Congress in Amsterdam. The results were published simultaneously in Circulation. BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled clinical study to assess the safety of one